Impact Biomedical Inc. (New York Stock Exchange Arca:IBO)
| Market Cap | 36.14M-45.7% |
| Revenue (ttm) | 35.00K+400.0% |
| Net Income | 789.00K+102.1% |
| EPS | 0.09+97.3% |
| Shares Out | 8.54M |
| PE Ratio | 47.00 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,279.437 |
| Open | 4.32 |
| Previous Close | 4.48 |
| Day's Range | 4.11 - 4.47 |
| 52-Week Range | 4.10 - 10.51 |
| Beta | 2.73 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About IBO
Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule electrophilically enhanced polyphenol compounds with potential applications in treating cancer, inflammatory diseases, and neurological conditions. Additionally, "Laetose" technology, a unique blend of sugar and inositol, is designed to counteract the inflammatory and metabolic responses usually triggered by sugar consumption. Impact BioMedical also creates "functional fragrance formulations," which are a series of fragrances incorporating specialized botanical ingredients for antimicrobial purposes, or as active additives in items like insect repellents, cleaning products, personal care items, and fabrics. Rounding out its offerings is the "Equivir/Equivir G" technology, a distinctive mix of polyphenols that has exhibited antiviral properties, suitable for use in health supplements and medications.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$IBO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in IBO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IBO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IBO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New IBO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IBO from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in IBO
| ETF | Est. Holding Size |
|---|---|
| VXFVanguard Extended Market ETF | $419.32K |
Estimated from each fund’s disclosed top holdings × AUM
IBO Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from IBO’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score